| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC3054 | Ldn-193188 | Novel inhibitor of phosphatidylcholine transfer protein (PC-TP) |
|
| DCC3055 | ldn-193191 | Potent and metabolically stable inhibitor of necroptosis, a regulated caspase-independent cell death pathway |
|
| DCC3056 | ldn-193594 | Novel cdk5/p25 kinase inhibitor |
|
| DCC3057 | Ldn-193665 | Novel potent tau kinase inhibitor, targeting CDK5/p25 and GSK3β |
|
| DCC3058 | ldn-211898 | Potent haspin kinase inhibitor |
|
| DCC3059 | Ldn-213844 | Novel ALK2 inhibitor |
|
| DCC3060 | Ldn-73794 | Competitive LRRK2 kinase inhibitor without affecting the GTPase activity |
|
| DCC3061 | L-dopa-snme3 | Precursor of 6-[18F]Fluoro-L-DOPA used for positron emission tomography (PET) scans. References: http://www.hindawi.com/journals/bmri/2014/674063/ |
|
| DCC3062 | Lds-751 | Nucleic acid binding fluorescent dye |
|
| DCC3063 | Ldt3 Dihydrochloride | Highly potent multi-target antagonists of both alpha1A- and alpha1D-adrenoceptors, and also of 5-HT1A receptors |
|
| DCC3064 | Ldt409 | Novel partial agonist of PPARα and PPARγ, providing distinct and favorable gene activation profiles for the treatment of diabetes and obesity |
|
| DCC3065 | Ldt5 Dihydrochloride | Highly potent multi-target antagonists of both alpha1A- and alpha1D-adrenoceptors, and also of 5-HT1A receptors |
|
| DCC3066 | Ldt8 Dihydrochloride | Highly potent multi-target antagonists of alpha1A- and alpha1D-adrenoceptors, and 5-HT1A receptors |
|
| DCC3067 | Ledgf/p75-in Inhibitor-6d | Novel inhibitor of the LEDGF/p75-IN interaction, potently inhibiting both the early and late stages of HIV-1 replication |
|
| DCC3068 | Lefucoxib | Cyclooxygenase-2 (COX-2) inhibitor |
|
| DCC3069 | Lei-101 | Novel, orally available and peripherally restricted selective cannabinoid CB2 receptor agonist |
|
| DCC3070 | Lei-301 | Novel potent inhibitor for the PLAAT family members, reducing the NAE levels, including anandamide, in cells overexpressing PLAAT2 or PLAAT5 |
|
| DCC3071 | Lem-06 | Novel inhibitor of nuclear receptor binding SET domain 2 (NSD2), against H3K36 methylation |
|
| DCC3072 | Lenaldekar | Novel inhibitor of T-cell expansion and autoimmune encephalomyelitis |
|
| DCC3073 | Lenalidomide-slf | Novel Electrophilic PROTAC that degrades nuclear proteins by engaging DCAF16 |
|
| DCC3074 | Leniquinsin | Phosphodiesterase inhibitor, acting as a vasodilator and showing antihypertensive effects |
|
| DCC3075 | Leo-134310 | Novel non-steroidal glucocorticoid receptor agonist |
|
| DCC3076 | Leo-29102 | Novel Soft-Drug Inhibitor of Phosphodiesterase 4 (PDE4) for Topical Treatment of Atopic Dermatitis |
|
| DCC3077 | Leq-506 | Orally bioavailable Smoothened (Smo) antagonist |
|
| DCC3078 | Leucettamine A | Leukotriene B4 receptor antagonist |
|
| DCC3079 | leucinethiol | Inhibitor of ERAAP function |
|
| DCC3080 | Levallorphan Tartrate Salt | Partial agonist (antagonist) at mu and delta opioid receptors. |
|
| DCC3081 | Levcromakalim Phosphate | Watersoluble prodrug of Levcromakalim, being more chemically robust and efficacious at lowering IOP with once daily dosing in a normotensive mouse model. |
|
| DCC3082 | Levocarnitine Propionate Hydrochloride | Natural carnitine derivative, playing a role in mitochondrial metabolism and demonstrating beneficial cardiovascular effects |
|
| DCC3083 | Levofloxacin Lactate | Respiratory quinolone antibiotic, exhibiting enhanced activity against the important respiratory pathogen Streptococcus pneumoniae |
|
